Table 6.

The highest percentage of patients presenting ≥30% improvement of MIDAS score is 31.0% after 3 months of combination therapy of onabotulinumtoxinA with anti-CGRP mAbs.

Study Report (Author and Year)	3 Months	6 Months	9 Months	12 Months
Blumenfeld et al., 2021 [47]	31.0% (n = 43/139)	29.6% (n = 33/112)	29.4% (n = 24/83)	27.1% (n = 18/66)
Mechtler et al., 2022 [48]	____________	____________	____________	____________